Search

Your search keyword '"Rose, Carsten"' showing total 337 results
Start Over Author "Rose, Carsten"
337 results on '"Rose, Carsten"'

12. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease

Author

Olsson, Eleonor, Winter, Christof, George, Anthony, Chen, Yilun, Howlin, Jillian, Tang, Man-Hung Eric, Dahlgren, Malin, Schulz, Ralph, Grabau, Dorthe, van Westen, Danielle, Fernö, Mårten, Ingvar, Christian, Rose, Carsten, Bendahl, Pär-Ola, Rydén, Lisa, Borg, Åke, Gruvberger-Saal, Sofia K, Jernström, Helena, and Saal, Lao H

Published
2015
Full Text
View/download PDF

18. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial

Author

Overgaard, Marie, Jensen, Maj-Britt, Overgaard, Jens, Hansen, Per S, Rose, Carsten, Andersson, Michael, Kamby, Claus, Kjaer, Mogens, Gadeberg, Carl C, Rasmussen, Birgitte Bruun, Blichert-Toft, Mogens, and Mouridsen, Henning T

Subjects
Breast cancer -- Risk factors, Breast cancer -- Care and treatment, Breast cancer -- Research, Radiotherapy -- Health aspects, Tamoxifen -- Health aspects
Published
1999

22. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy

Author

Overgaard, Marie, Hansen, Per S., Overgaard, Jens, Rose, Carsten, Andersson, Michael, Bach, Flemming, Kjaer, Mogens, Gadeberg, Carl C., Mouridsen, Henning T., Jensen, Maj-Britt, and Zedeler, Karin

Subjects
Breast cancer -- Care and treatment, Chemotherapy -- Evaluation, Radiotherapy -- Evaluation, Mastectomy -- Health aspects
Abstract

Radiotherapy in combination with chemotherapy may prolong life and reduce the risk of relapse in women with breast cancer who have had a mastectomy. Researchers randomly assigned 1,708 such women to receive only chemotherapy with cyclophosphamide, methotrexate and fluorouracil or chemotherapy plus radiotherapy. The frequency of relapse or metastasis was 9% in the women who received chemotherapy and radiotherapy compared to 32% in those who received chemotherapy. Ten-year survival rates were 54% in those given chemotherapy and radiotherapy compared to 45% in those given chemotherapy.

Published
1997

25. Diagnostic spectrum and time intervals in Sweden's first diagnostic center for patients with nonspecific symptoms of cancer

Author

Stenman, Emelie, Palmér, Karolina, Rydén, Stefan, Sävblom, Charlotta, Svensson, Inga, Rose, Carsten, Ji, Jianguang, Nilbert, Mef, Sundquist, Jan, Stenman, Emelie, Palmér, Karolina, Rydén, Stefan, Sävblom, Charlotta, Svensson, Inga, Rose, Carsten, Ji, Jianguang, Nilbert, Mef, and Sundquist, Jan

Abstract

BACKGROUND: Fast-track referral is an increasingly used method for diagnostic evaluation of patients suspected of having cancer. This approach is challenging and not used as often for patients with only nonspecific symptoms. In order to expedite the diagnostics for these patients, we established Sweden's first Diagnostic Center (DC) focusing on outcomes related to diagnoses and diagnostic time intervals.MATERIAL AND METHODS: The study was designed as a prospective cohort study. Patients aged ≥18 years who presented in primary care with nonspecific symptoms of a serious disease were eligible for referral to the DC after having completed an initial investigation. Acceptable diagnostic time intervals were defined to be a maximum of 15 days in primary care and 22 days at the DC. Diagnostic outcome, length of diagnostic time intervals and patient satisfaction were evaluated.RESULTS: A total of 290 patients were included in the study. Cancer was diagnosed in 22.1%, other diseases in 64.1%, and no diagnosis was identified in 13.8% of these patients. Patients diagnosed with cancer were older, had shorter patient interval (time from first symptom to help-seeking), shorter DC-interval (time from referral decision in primary care to diagnosis) and showed a greater number of symptoms compared to patients with no diagnosis. The median primary care interval was 21 days and the median DC interval was 11 days. Few symptoms, no diagnosis, female sex, longer patient interval, and incomplete investigations were associated with prolonged diagnostic time intervals. Patient satisfaction was high; 86% of patients reported a positive degree of satisfaction with the diagnostic procedures.CONCLUSIONS: We demonstrated that the DC concept is feasible with a diagnosis reached in 86.2% of the patients in addition to favorable diagnostic time intervals at the DC and a high degree of patient satisfaction.

Published
2019

32. Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies

Author

Ingvar Christian, Loman Niklas, Klintman Marie, Bendahl Pär-Ola, Romero Quinci, Rydén Lisa, Rose Carsten, Grabau Dorthe, and Borgquist Signe

Subjects
core biopsy, Ki67, breast cancer, proliferation, neo-adjuvant, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background An increasing number of neo-adjuvant breast cancer studies are being conducted and a novel model for tumor biological studies, the "window-of-opportunity" model, has revealed several advantages. Change in tumor cell proliferation, estimated by Ki67-expression in pre-therapeutic core biopsies versus post-therapeutic surgical samples is often the primary end-point. The aim of the present study was to investigate potential differences in proliferation scores between core biopsies and surgical samples when patients have not received any intervening anti-cancer treatment. Also, a lack of consensus concerning Ki67 assessment may raise problems in the comparison of neo-adjuvant studies. Thus, the secondary aim was to present a novel model for Ki67 assessment. Methods Fifty consecutive breast cancer cases with both a core biopsy and a surgical sample available, without intervening neo-adjuvant therapy, were collected and tumor proliferation (Ki67, MIB1 antibody) was assessed immunohistochemically. A theoretical model for the assessment of Ki67 was constructed based on sequential testing of the null hypothesis 20% Ki67-positive cells versus the two-sided alternative more or less than 20% positive cells.. Results Assessment of Ki67 in 200 tumor cells showed an absolute average proliferation difference of 3.9% between core biopsies and surgical samples (p = 0.046, paired t-test) with the core biopsies being the more proliferative sample type. A corresponding analysis on the log-scale showed the average relative decrease from the biopsy to the surgical specimen to be 19% (p = 0.063, paired t-test on the log-scale). The difference was significant when using the more robust Wilcoxon matched-pairs signed-ranks test (p = 0.029). After dichotomization at 20%, 12 of the 50 sample pairs had discrepant proliferation status, 10 showed high Ki67 in the core biopsy compared to two in the surgical specimen (p = 0.039, McNemar's test). None of the corresponding results for 1000 tumor cells were significant - average absolute difference 2.2% and geometric mean of the ratios 0.85 (p = 0.19 and p = 0.18, respectively, paired t-tests, p = 0.057, Wilcoxon's test) and an equal number of discordant cases after dichotomization. Comparing proliferation values for the initial 200 versus the final 800 cancer cells showed significant absolute differences for both core biopsies and surgical samples 5.3% and 3.2%, respectively (p < 0.0001, paired t-test). Conclusions A significant difference between core biopsy and surgical sample proliferation values was observed despite no intervening therapy. Future neo-adjuvant breast cancer studies may have to take this into consideration.

Published
2011
Full Text
View/download PDF

34. The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size

Author

Simonsson, Maria, Björner, Sofie, Markkula, Andrea, Nodin, Björn, Jirström, Karin, Rose, Carsten, Borgquist, Signe, Ingvar, Christian, and Jernström, Helena

Subjects
Breast cancer, Oral contraceptives, Cancer and Oncology, Cyclooxygenase-2, Prognosis, Non-steroidal anti-inflammatory drugs
Abstract

The association between tumor cyclooxygenase 2 (COX-2) expression and breast cancer prognosis has been inconsistent. The purpose of this study was to evaluate the prognostic significance of COX-2 tumor expression according to adjuvant treatment, and potential effect modifications of non-steroid anti-inflammatory drug (NSAID) use, and other tumor and lifestyle factors. A prospective cohort of 1,116 patients with primary breast cancer in Lund, Sweden, included 2002-2012 was followed until June 2014 (median 5 years). Tumor-specific COX-2 expression was evaluated on tissue microarrays using immunohistochemistry. Associations between COX-2 intensity (negative, weak-moderate, high) and patient and tumor characteristics as well as prognosis were analyzed. Tumor-specific COX-2 expression was available for 911 patients and was significantly associated with higher age at diagnosis and less aggressive tumor characteristics. Higher COX-2 expression was associated with lower risk for breast cancer events during the first five years of follow-up, adjHR 0.60 (95%CI: 0.37-0.97), per category. The association between COX-2 expression and prognosis was significantly modified by oral contraceptive (OC) use (Pinteraction=0.048), preoperative NSAID use (Pinteraction=0.009), and tumor size (Pinteraction=0.039). COX-2 negativity was associated with increased risk for events during the first five years in ever OC users, adjHR 1.94 (1.01-3.72) and during the 11-year follow-up in preoperative NSAID users, adjHR 4.51 (1.18-11.44) as well as in patients with large tumors, adjHR 2.57 (1.28-5.15). In conclusion, this study, one of the largest evaluating COX-2 expression in breast cancer, indicates that the prognostic impact of COX-2 expression depends on host factors and tumor characteristics.

Published
2017

35. Adjuvant radiotherapy and risk of contralateral breast cancer

Author

Storm, Hans H., Andersson, Michael, Boice, John D., Jr., Blettner, Maria, Stovall, Marilyn, Mouridsen, Henning T., Dombernowsky, Per, Rose, Carsten, Jacobsen, Anders, and Pedersen, Mogens

Subjects
Breast cancer -- Risk factors, Tumors, Radiation-induced -- Risk factors, Radiotherapy -- Physiological aspects, Health
Abstract

Background: The risk of contralateral breast cancer is increased twofold to fivefold for breast cancer patients. A registry-based cohort study in Denmark suggested that radiation treatment of the first breast cancer might increase the risk for contralateral breast cancer among 10-year survirors. Purpose: Our goal was to assess the role of radiation in the development of contralateral breast cancer. Methods: A nested case-control study was conducted in a cohort of 56540 women in Denmark diagnosed with invasive breast cancer from 1943 through 1978. Case patients were 529 women who developed contralateral breast cancer 8 or more years after first diagnosis. Controls were women with breast cancer who did not develop contralateral breast cancer. One control was matched to each case patient on the basis of age, calendar year of initial breast cancer diagnosis, and survival time. Radiation dose to the contralateral breast was estimated for each patient on the basis of radiation measurements and abstracted treatment information. The anatomical position of each breast cancer was also abstracted from medical records. Results: Radiotherapy had been administered to 82.4% of case patients and controls, and the mean radiation dose to the contralateral breast was estimated to be 2.51 Gy. Radiotherapy did not increase the overall risk of contralateral breast cancer (relative risk = 1.04; 95% confidence interval = 0.74-1.46), and there was no evidence that risk varied with radiation dose, time since exposure, or age at exposure. The second tumors in case patients were evenly distributed in the medial, lateral, and central portions of the breast, a finding that argues against a causal role of radiotherapy in tumorigenesis. Conclusions: The majority of women in our series were perimenopausal or postmenopausal (53% total versus 38% premenopausal and 9% of unknown status) and received radiotherapy at an age when the breast tissue appears least susceptible to the carcinogenic effects of radiation. Based on a dose of 2.51 Gy and estimates of radiation risk from other studies, a relative risk of only 1.18 would have been expected for a population of women exposed at an average age of 51 years. Thus, our data provide additional evidence that there is little if any risk of radiation-induced breast cancer associated with exposure of breast tissue to low-dose radiation (e.g., from mammographic x rays or adjuvant radiotherapy) in later life. [J Natl Cancer Inst 84:1245-1250, 1992]

Published
1992

37. Coffee Is Associated With Lower Breast Tumor Insulin-Like Growth Factor Receptor 1 Levels in Normal-Weight Patients and Improved Prognosis Following Tamoxifen or Radiotherapy Treatment

Author

Björner, Sofie, primary, Rosendahl, Ann H., additional, Tryggvadottir, Helga, additional, Simonsson, Maria, additional, Jirström, Karin, additional, Borgquist, Signe, additional, Rose, Carsten, additional, Ingvar, Christian, additional, and Jernström, Helena, additional

Published
2018
Full Text
View/download PDF

42. Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups

Author

Björner, Sofie, primary, Rosendahl, Ann H., additional, Simonsson, Maria, additional, Markkula, Andrea, additional, Jirström, Karin, additional, Borgquist, Signe, additional, Rose, Carsten, additional, Ingvar, Christian, additional, and Jernström, Helena, additional

Published
2016
Full Text
View/download PDF

49. Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.

Author

Gustbée, Emma, Tryggvadottir, Helga, Markkula, Andrea, Simonsson, Maria, Nodin, Björn, Jirström, Karin, Rose, Carsten, Ingvar, Christian, Borgquist, Signe, Jernström, Helena, Gustbée, Emma, Tryggvadottir, Helga, Markkula, Andrea, Simonsson, Maria, Nodin, Björn, Jirström, Karin, Rose, Carsten, Ingvar, Christian, Borgquist, Signe, and Jernström, Helena

Abstract

The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results